Whitehawk Therapeutics, Inc. Cash Flow Statement
WHWK|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Whitehawk Therapeutics, Inc. used $60M in operating cash flow and negative free cash flow of $61M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$63.7M | -$65.8M | -$60.5M | -$110.1M | -$3.5M | -$23.3M | -$10.4M | -$21.4M |
| Depreciation & Amortization | $193.0K | $169.0K | $159.0K | $105.0K | $9.0K | $76.5K | $46.7K | $51.3K |
| Operating Cash Flow | -$59.5M | -$59.7M | -$49.6M | -$22.4M | -$12.7M | -$23.9M | -$5.8M | -$18.9M |
| Capital Expenditures | $1.7M | $4.0M | $444.0K | $46.0K | $46.0K | $237.0K | $37.9K | $8.9K |
| Free Cash Flow | -$61.2M | -$63.6M | -$50.1M | -$22.5M | -$12.7M | -$24.1M | -$5.8M | -$18.9M |
| Dividends Paid | - | - | - | $4.4M | $4.4M | - | - | - |
| FCF Margin | -235.6% | -261.3% | -357.7% | -160.5% | -87.4% | - | -29.0% | -1416.9% |